menu

Loading...

COEP Stock: Price, Forecast, Financials & AI Analysis

Loading chart...

High

12.980

Open

11.580

VWAP

12.48

Vol

50.73K

Mkt Cap

74.79M

Low

11.490

Amount

633.29K

EV/EBITDA(TTM)

--

Total Shares

5.76M

EV

61.39M

EV/OCF(TTM)

--

P/S(TTM)

77.51

Coeptis Therapeutics Holdings, Inc. is a biopharmaceutical and technology company. The Company is focused on developing cell therapy platforms for cancer, autoimmune, and infectious diseases. Its product portfolio is highlighted by assets licensed from Deverra Therapeutics, including an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. It is developing a universal, multi-antigen CAR technology licensed by the University of Pittsburgh (SNAP-CAR), and the GEAR cell therapy and companion diagnostic platforms in collaboration with VyGen-Bio and medical researchers at the Karolinska Institute. Its NexGenAI Affiliates Network platform offers AI-powered marketing software and robotic process automation capabilities. The Company’s subsidiaries include Coeptis Therapeutics, Inc., Coeptis Pharmaceuticals, Inc., GEAR Therapeutics, Inc. and SNAP Biosciences, Inc.

Show More

Events Timeline

(ET)

2026-01-06

08:40:00

Coeptis Therapeutics Merger Registration Statement with Z Squared Declared Effective

2025-07-22 (ET)

2025-07-22

08:38:38

Coeptis Therapeutics extinguishes convertible note

2025-06-26 (ET)

2025-06-26

08:37:23

Coeptis files registration statement for proposed Z Squared transaction

2025-05-28 (ET)

2025-05-28

08:29:40

Monarch Therapeutics, SNAP Biosciences enter licensing agreement

2025-04-25 (ET)

2025-04-25

08:36:58

Coeptis Therapeutics, Z Squared enter merger agreement

2025-04-17 (ET)

2025-04-17

08:39:07

Coeptis Therapeutics announces establishment of new technology hub in India

2025-03-07 (ET)

2025-03-07

08:39:50

Coeptis' NexGenAI Affiliates Network partners with Nuburu

2025-02-20 (ET)

2025-02-20

07:31:19

Coeptis' NexGenAI Affiliates Network & MarketLeverage partner in marketing

2025-02-19 (ET)

2025-02-19

20:16:14

Coeptis Therapeutics' NexGenAI partners with Arketyp Valu

2025-01-30 (ET)

2025-01-30

07:32:35

Coeptis Therapeutics announces rebranding to Coeptis

News

NASDAQ.COM

01-28NASDAQ.COM

Healthcare Stocks Surge in After-Hours Trading

Globenewswire

01-06Globenewswire

Coeptis Therapeutics Secures SEC Approval for Merger with Z Squared Inc.

Globenewswire

2025-10-07Globenewswire

SHAREHOLDER RIGHTS NOTICE: Halper Sadeh LLC Probes BFIN, COEP, ARIS, CIO for Shareholder Interests

Globenewswire

2025-10-07Globenewswire

URGENT: M&A Class Action Firm Ongoing Investigation into the Merger Involving BFIN, ARIS, CIO, and COEP

PRnewswire

2025-08-28PRnewswire

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CYBR, UNP, COEP on Behalf of Shareholders

Globenewswire

2025-07-05Globenewswire

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SAGE, COEP, AVDX on Behalf of Shareholders

Valuation Metrics

The current forward P/E ratio for Coeptis Therapeutics Holdings Inc (COEP.O) is -4.31, compared to its 5-year average forward P/E of -17.36. For a more detailed relative valuation and DCF analysis to assess Coeptis Therapeutics Holdings Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

-17.36

Current PE

-4.31

Overvalued PE

21.89

Undervalued PE

-56.62

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

-2.49

Current EV/EBITDA

-5.26

Overvalued EV/EBITDA

0.16

Undervalued EV/EBITDA

-5.15

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

N/A

5Y Average PS

4.55

Current PS

0.00

Overvalued PS

15.20

Undervalued PS

-6.10

Financials

AI Analysis

Annual

Quarterly

Whales Holding COEP

Trading Trends

People Also Watch

Frequently Asked Questions

What is Coeptis Therapeutics Holdings Inc (COEP) stock price today?

The current price of COEP is 12.98 USD — it has increased 13.46

What is Coeptis Therapeutics Holdings Inc (COEP)'s business?

Coeptis Therapeutics Holdings, Inc. is a biopharmaceutical and technology company. The Company is focused on developing cell therapy platforms for cancer, autoimmune, and infectious diseases. Its product portfolio is highlighted by assets licensed from Deverra Therapeutics, including an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. It is developing a universal, multi-antigen CAR technology licensed by the University of Pittsburgh (SNAP-CAR), and the GEAR cell therapy and companion diagnostic platforms in collaboration with VyGen-Bio and medical researchers at the Karolinska Institute. Its NexGenAI Affiliates Network platform offers AI-powered marketing software and robotic process automation capabilities. The Company’s subsidiaries include Coeptis Therapeutics, Inc., Coeptis Pharmaceuticals, Inc., GEAR Therapeutics, Inc. and SNAP Biosciences, Inc.

What is the price predicton of COEP Stock?

Wall Street analysts forecast COEP stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for COEP is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Coeptis Therapeutics Holdings Inc (COEP)'s revenue for the last quarter?

Coeptis Therapeutics Holdings Inc revenue for the last quarter amounts to 237.44K USD, decreased

What is Coeptis Therapeutics Holdings Inc (COEP)'s earnings per share (EPS) for the last quarter?

Coeptis Therapeutics Holdings Inc. EPS for the last quarter amounts to -0.58 USD, decreased -33.33

How many employees does Coeptis Therapeutics Holdings Inc (COEP). have?

Coeptis Therapeutics Holdings Inc (COEP) has 5 emplpoyees as of March 05 2026.

What is Coeptis Therapeutics Holdings Inc (COEP) market cap?

Today COEP has the market capitalization of 74.79M USD.